Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.
about
β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastomac-Met as a Target for Personalized TherapyMetabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentialityPhase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.Four individually druggable MET hotspots mediate HGF-driven tumor progression.Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern.The evolving landscape of glioblastoma stem cells.Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitorsHypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy.The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients.Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomasPhase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumorsCombination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma modelsPerioperative cerebral ischemia promote infiltrative recurrence in glioblastoma.Molecular and functional evaluation of a novel HIF inhibitor, benzopyranyl 1,2,3-triazole compound.Talin1 targeting potentiates anti-angiogenic therapy by attenuating invasion and stem-like features of glioblastoma multiforme.Bevacizumab for glioblastoma: current indications, surgical implications, and future directionsVaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance.Role of collagen matrix in tumor angiogenesis and glioblastoma multiforme progression.MET/HGF pathway activation as a paradigm of resistance to targeted therapies.GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance.Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancerTargeting angiogenesis in renal cell carcinoma.Current status of antiangiogenic therapies for glioblastomas.Resistance to antiangiogenic therapy.Resistance to antiangiogenic therapies.Approaches for measuring signalling plasticity in the context of resistance to targeted cancer therapies.Tivantinib: critical review with a focus on hepatocellular carcinoma.Antiangiogenic therapies for glioblastoma.Bevacizumab in high-grade gliomas: past, present, and future.Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.Tivantinib (ARQ197) in hepatocellular carcinoma.Recent advances in targeted therapy for glioblastoma.Extraneural metastases in glioblastoma patients: two cases with YKL-40-positive glioblastomas and a meta-analysis of the literature.Glioblastoma targeted therapy: updated approaches from recent biological insights.Recent advance in molecular angiogenesis in glioblastoma: the challenge and hope for anti-angiogenic therapy.
P2860
Q24564890-834E77C8-7520-4B53-A7C9-2A91DA365A3DQ26775483-32A2B3CD-96A2-441A-BC65-0694BE770254Q27025007-39B41211-2550-46EF-B1F3-7131F085ABA2Q30278053-AE24FECA-311F-4F08-85FD-4EFBFEF22043Q30581656-C01D278D-3CCC-42B4-B98D-FE387DE26C9CQ33624367-AD17227E-1B39-47E2-B883-F3DC653FFDD2Q33652614-FDC0C771-BB0B-479C-AC19-9657BD63DCDBQ33853991-6FFDFBFC-BD2C-4849-8046-0EE6AD61E5E1Q33888739-717AA5C3-AB07-439A-B86A-D746A4B0BC12Q34227712-1E6155A9-86FB-463B-BB3F-0A77F47510B6Q34293163-B2DF2A7B-2D6D-4E51-90FE-6065A07AA6BAQ34807753-14C630AE-B008-4383-A91E-7F8B07946E16Q34964958-9E06BE15-6061-4193-AE4E-989488764F2DQ34978329-E838BBC2-5864-47DF-9A97-350DFA4AAAB6Q35987408-1B2F28FF-7C79-4D61-9EDD-5DDC0B8760D3Q36229899-D9D67795-DB66-433A-BFF0-5130A948C776Q36413742-1BFB356D-7C55-4EDC-B248-9A8B6525FAE5Q36822207-C1B57150-9FD2-4313-A4D1-5F0447D2C94EQ37014134-8E8B7733-D0BF-4BAC-94B0-ED204CC91B7CQ37153834-04B7B59C-8D3B-4B9D-AC6E-D411F0A97019Q37218231-12D8ED3B-CD34-4FED-895C-C0A4F9E1A933Q37597850-F6050696-3D1B-49F2-97C3-C1B91F7DECBBQ37599547-91A783E4-09F8-4AA5-B346-6D7865D02FDCQ37687269-E1ADFD6A-3429-4DA9-A719-4E2F7474CD7AQ37702041-513D894C-597A-49AC-8EF4-E6D397F027ADQ38125964-AC03A1DE-616E-47F5-BCEC-9CAC49565347Q38132231-0931B18B-A0AE-4ED5-ACC6-90155459CD97Q38169761-30CEBCBC-F49B-42F7-8744-010B1542D5E9Q38197943-93028C31-0DE1-4229-8EDE-2DA652557F4BQ38232852-91484DC4-2CAE-4EC2-985E-A3EBFED9C9A1Q38238607-660F212A-9E8D-4DA0-902F-6F98F368565AQ38259343-463C28C5-2603-439C-8CDA-B6F028406CA2Q38264310-25E9254C-99AE-47C4-B5CC-F47387B5F206Q38386873-1C45DFD0-4E83-4585-9233-5F44C4D6ED19Q38498207-6BE234C0-6950-478B-AEDA-54401EDEAD35Q38513062-3533D2C9-6171-4159-AA9A-D102D1556629Q38539386-DB8CB450-8059-4008-A102-5FCF2E550DDCQ38554801-F5BF65E7-FFD5-4D7B-B500-0268456462E6Q38597700-AB729940-8751-4D38-971A-2248AE8CC5F2Q38599484-C8A74A59-2724-40B7-A0E8-D5693AFCF30F
P2860
Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Gene expression profile identi ...... angiogenic therapy resistance.
@en
Gene expression profile identi ...... angiogenic therapy resistance.
@nl
type
label
Gene expression profile identi ...... angiogenic therapy resistance.
@en
Gene expression profile identi ...... angiogenic therapy resistance.
@nl
prefLabel
Gene expression profile identi ...... angiogenic therapy resistance.
@en
Gene expression profile identi ...... angiogenic therapy resistance.
@nl
P2093
P2860
P1476
Gene expression profile identi ...... angiogenic therapy resistance.
@en
P2093
Arman Jahangiri
Gabriele Bergers
Jesse Paquette
Kirsten M Bjorgan
Liane M Miller
Manish K Aghi
Maxwell W Tom
Michael De Lay
Myriam M Chaumeil
P2860
P304
P356
10.1158/1078-0432.CCR-12-1281
P407
P50
P577
2013-01-10T00:00:00Z